BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Rhea-AI Summary

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced the launch of a preclinical study led by Dr. Randy Seeley to evaluate the efficacy of its drug candidate BF-114 in treating obesity, NAFLD, and NASH. The study is expected to be completed in Q2 2024 and aims to complement the company’s AI platform for identifying new pathways to target obesity and metabolic diseases. With the market for obesity drugs projected to exceed $77 billion by 2030, the potential impact of BF-114 on these conditions is significant.

The market for obesity drugs is projected to exceed $77 billion by 2030

Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study

GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action (MOA). The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.

BF-114 is a siRNA molecule that targets Beta-II Spectrin (SPTBN1) and has shown promising results in animal models for obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), all of which are areas of significant unmet medical need. Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes. Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.

“The market for obesity drugs is projected to exceed $77 billion by 2030, and pharmaceutical companies around the world have recognized the importance of targeting multiple pathways to treat this condition,” said Vin Singh, CEO of BullFrog AI. “Preclinical data suggest that BF-114 can have a significant impact on obesity and related metabolic conditions, and we look forward to working with Dr. Seeley, a recognized expert in the obesity field, to further define the extent and mechanism for this effect. Findings from this study will be key in helping to establish and progress discussions with potential pharmaceutical partners.”

“Obesity and related metabolic diseases represent a major health issue in the US and around the world,” said Seeley. “I look forward to the opportunity to work with the team at BullFrog AI to make progress on BF-114 in the hopes that we can begin to bring new and effective treatment modalities beyond what is currently available to bear on these diseases.”

About BullFrog AI

BullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. Through its partnerships with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

For more information visit BullFrog AI at:

Website: https://bullfrogai.com

LinkedIn: https://www.linkedin.com/company/bullfrogai/

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447

SOURCE: BullFrog AI Holdings, Inc.

FAQ

What is the ticker symbol for BullFrog AI Holdings, Inc.?

The ticker symbols for BullFrog AI Holdings, Inc. are BFRG and BFRGW on the NASDAQ stock exchange.

What is the purpose of the preclinical study announced by BullFrog AI Holdings, Inc.?

The preclinical study aims to evaluate the efficacy of the drug candidate BF-114 in treating obesity, NAFLD, and NASH, as well as to elucidate the mechanism of action.

Who is leading the preclinical study for BullFrog AI Holdings, Inc.?

Dr. Randy Seeley, a recognized expert in the obesity field, is leading the preclinical study.

What is the market projection for obesity drugs by 2030?

The market for obesity drugs is projected to exceed $77 billion by 2030.

What are the potential areas of impact for BF-114?

BF-114 has shown promising results in animal models for obesity, NAFLD, and NASH, all of which are areas of significant unmet medical need.

What are the expected outcomes of the preclinical study?

The findings from the preclinical study will be key in establishing and progressing discussions with potential pharmaceutical partners for BF-114.

What are the potential implications of BF-114 for the treatment of obesity and related metabolic diseases?

BF-114 has the potential to bring new and effective treatment modalities beyond what is currently available to bear on these diseases.

What are the current medical care costs for obesity-related health problems?

Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.